Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
Published Sep 1, 1986 · M. Pavone‐Macaluso, H. J. Voogt, G. Viggiano
The Journal of urology
175
Citations
3
Influential Citations
Abstract
Abstract removed due to Elsevier request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
Key takeawayMedroxyprogesterone acetate has a less favorable course and shorter survival than cyproterone acetate and diethylstilbestrol in treating advanced prostatic cancer, with no significant difference between the two drugs.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.